http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112011620-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate | 2020-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-112011620-B |
titleOfInvention | Application of circ-SLC38A1 as target in medicine for inhibiting bladder cancer cells |
abstract | The invention belongs to the technical field of tumor biological gene therapy, relates to a biological marker and a target point for diagnosing and treating bladder cancer, and particularly relates to application of circ-SLC38A1 as a target point in medicines for inhibiting bladder cancer cells. The invention discloses the expression of circ-SLC38A1 in tumor tissues of patients with bladder cancer and the function of circ-SLC38A1 in bladder cancer cells. The first discovery shows that the circ-SLC38A1 can be used as a bladder cancer diagnosis biomarker and a drug treatment target. As compared to normal controls, circ-SLC38A1 was significantly upregulated in tumor tissue in bladder cancer patients. The result of the invention shows that the interference with circ-SLC38A1 can inhibit the migration and invasion capacity of bladder cancer cells, shows that the circ-SLC38A1 plays the role of cancer promotion genes in the occurrence and development of bladder cancer, and provides a new target for clinical treatment of bladder cancer. |
priorityDate | 2020-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 190.